Controversy over a leaked Gilead Sciences document that stated studies of its hopeful coronavirus treatment, Remdesivir, have proven inconclusive. Gilead has come out saying the document contained inappropriate characterization blaming some of the issues on low enrollment in the study. Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joins "Squawk Box" to discuss.